United States: 2013 – The Health Law Year In Review

As 2013 draws to a close, we are pleased to look back on the year that was and highlight some of the key developments in the ever-changing field of health law. While a great deal of attention was focused on the implementation of the Affordable Care Act, 2013 also included a number of significant developments in other areas, including information privacy and security, antitrust, fraud and abuse, and drug safety. We have compiled a list of 10 important issues that affect a broad range of health care industry clients. If you would like to learn more about these or other health law issues, please contact any of the attorneys in the Health Care practice group at Bradley Arant Boult Cummings LLP.

1. HITECH Omnibus Rule

In January, the Department of Health and Human Services (HHS) issued the long-awaited omnibus final rule to modify the Health Insurance Portability and Accountability Act of 1996 (HIPAA) pursuant to the Health Information Technology for Economic and Clinical Health Act (HITECH). The final rule made a number of important changes to the HIPAA rules, including making business associates and their subcontractors directly liable for violations of certain of the HIPAA rules, strengthening the enforcement provisions of HIPAA, modifying the breach notification requirement by creating a presumption that a breach has occurred unless there is a low probability that the information at issue has been compromised, and prohibiting most health plans from using or disclosing genetic information for underwriting purposes. The issuance of the final rule coupled with several high-profile settlements resulted in many health care organizations (and their business partners) renewing their focus on HIPAA compliance in 2013. For our comprehensive coverage of the final rule, click here.

2. Physician Payment Sunshine Act Final Rule

The Centers for Medicare & Medicaid Services (CMS) finalized the rule implementing the Physician Payment Sunshine Act on February 1. The final rule requires certain manufacturers of covered drugs, devices, and biological and medical supplies operating in the United States to annually disclose most direct and indirect payments and other "transfers of value" made to physicians and certain teaching hospitals. Applicable manufacturers and applicable group purchasing organizations also must report ownership or investment interests held by physicians or immediate family members of physicians. Payments subject to reporting include research-related payments, consulting fees, honoraria, faculty and speaker compensation, grants, gifts, entertainment, food, travel, charitable contributions, royalties or licenses, current or prospective ownership or investment interests, and any other nature of payment or transfer of value. Failure to report may result in civil monetary penalties. Click here for further detail regarding the final rule.

3. Key Antitrust Developments

The Federal Trade Commission (FTC) continued its aggressive enforcement against provider mergers it believed to be anticompetitive, expanding beyond hospital transactions to challenges to mergers and acquisitions of physician practices. In February, the FTC prevailed in a significant U.S. Supreme Court case about the state action doctrine as applied to the merger of two hospitals (FTC v. Phoebe Putney Health System, Inc., No. 11-1160, 568 U.S. __ (2013)). The FTC had asserted that the acquisition of Palmyra Park by the Phoebe Putney Health System was essentially a "merger to monopoly and would allow Phoebe Putney to raise prices for general acute-care hospital services charged to commercial health plans, as well as diminish healthcare quality and service." Click here for our previous coverage of the decision.

In March, the FTC filed a lawsuit against St. Luke's Health Care System seeking to enjoin the acquisition of Idaho's largest independent multi-specialty physician practice group. The case marks the first time that the FTC has litigated to trial a matter involving a hospital's acquisition of a physician practice. The case may define how the courts view hospital acquisitions of physician practices for years to come and may signal a renewed retrospective review of health care mergers by the FTC. A decision is expected from the court in the first quarter of 2014.

In addition to its law enforcement activities, the FTC issued its first guidance for clinically integrated networks since passage of the Affordable Care Act in February. The advisory opinion was issued in response to a proposal by the Norman Physician Hospital Organization to form a clinically integrated health care network. The advisory opinion may be viewed as a road map for successful clinical integration of health care providers. For more on the advisory opinion, click here.

4. OIG Special Fraud Alert on Physician-Owned Distributorships

The Office of Inspector General (OIG) published a special fraud alert on March 26 in which it labeled physician-owned distributorships (PODs) "inherently suspect." The OIG defined PODs as physician-owned entities that derive revenue from selling, designing, or manufacturing medical devices (including surgical implants) or instruments. The special fraud alert follows intense congressional scrutiny of PODs in recent years, which included a June 2011 report in which the Senate Finance Committee suggested that PODs create financial incentives for physicians to make patient treatment decisions based on economic gain. The special fraud alert is notable for its unequivocal suspicion of an entire class of health care businesses. The alert has already led to a lawsuit against HHS and the OIG by an implant and device manufacturer alleging that the alert has had a chilling effect on the PODs industry (Reliance Medical Systems, LLC v. HHS, U.S. District Court, Central District of California). For our previous coverage of the special fraud alert, click here.

5. Inpatient Admission Criteria and the "Two Midnight" Rule

In its final Inpatient Prospective Payment System rule for 2014, CMS announced the so-called two midnight rule, whereby payment for Medicare Part A hospital inpatient services generally will be considered appropriate if the admitting physician expects that the beneficiary will require a stay that spans at least two midnights. The two midnight rule will operate as a presumption of medical necessity under which inpatient stays that donot span two midnights will be subject to prepayment review. Although CMS claimed in the final rule that the two midnight requirement merely clarifies existing policies for inpatient admissions, hospitals have objected that the new rule actually extends the generally accepted 24-hour stay standard for inpatient admissions. The American Hospital Association and others have organized a strong backlash against the new requirement, including a legislative proposal (the Two-Midnight Rule Delay Act, H.R. 3698). Opponents of the rule have already succeeded in delaying its enforcement by CMS and recovery auditors. The future of the rule likely will play out well into 2014.

6. Key Stark Law Rulings

The year also brought significant developments in a pair of closely watched cases involving alleged violations of the federal physician self-referral prohibition, commonly known as the Stark Law. On September 30, in U.S. ex rel. Drakeford v. Tuomey Healthcare System, a federal district court in South Carolina ordered that a hospital system pay more than $237 million for violations of the Stark Law and the federal False Claims Act. The order, entered nearly eight years after the case was filed, followed a May 2013 jury verdict finding that Tuomey violated the Stark Law and False Claims Act by entering into part-time employment contracts with a number of physicians that varied with and took into account the volume or value of the physicians' referrals.

On November 13, in U.S. ex rel. Baklid-Kunz v. Halifax Medical Center, a federal district court in Florida issued an order granting partial summary judgment to the United States in a case concerning whether a hospital's payment of bonus compensation to employed medical oncologists violated the Stark Law. The court found that the bonus payments, which were made from a pool consisting of the oncology program's profits and distributed to the physicians in proportion to their personally performed services, took into account the volume or value of referrals by the physicians and therefore failed to meet the requirement of the Stark Law's bona fide employment exception. For previous coverage regarding these cases, click here.

7. Drug Quality and Security Act

In response to the 2012 fungal meningitis outbreak linked to pharmacy compounding, Congress amended the Federal Food, Drug, and Cosmetic Act with respect to drug compounding and supply chain traceability in November. The objective of the amendments is to replace the inconsistent and fragmented patchwork of state laws with uniform standards for drug distribution safety and provide a system for establishing the pedigree of prescription drugs. Under the Drug Quality and Security Act, compounding pharmacies electing to meet certain uniform national standards for compounding, labeling, and quality assurance reporting may register annually with the Food and Drug Administration (FDA) as "outsourcing facilities" and be subject to FDA inspections and adverse event reporting. The Act also requires HHS to establish national standards for the licensing of wholesale distributors and third-party warehousing and logistics providers within two years and phase in regulatory requirements to facilitate product tracking at the transaction level through the drug supply chain.

8. Mental Health Parity Act Final Rule

In November, CMS joined the IRS and the U.S. Department of Labor in issuing final rules under the Mental Health Parity and Addiction Equity Act of 2008 (MHPAEA). The final rules follow the interim final regulations issued in January 2010, the passage of the Affordable Care Act, and several rounds of interpretive FAQs to clarify obligations on group health insurance issuers and group health plans for placing mental health and substance use disorder benefits in parity with general medical/surgical benefits and to extend the MHPAEA to the individual insurance market. The final rules apply to financial requirements (e.g., copays and deductibles), quantitative treatment limitations (e.g., number of visits and days of coverage), and nonquantitative treatment limitations (e.g., reimbursement rates and medical management standards relating to medical necessity).

In general, the final rules provide that a plan may not impose a financial requirement or quantitative treatment limitation on mental health and substance use disorder benefits in any classification that is more restrictive than the predominant financial requirement or quantitative treatment limitation for substantially all medical/surgical benefits in the same classification. Similarly, a plan may not impose nonquantitative treatment limitations with respect to a mental health and substance use disorder benefit in any classification unless such limitations are comparable to the limitations imposed by the plan for medical/surgical benefits in the same classification. Notably, the final rules eliminated entirely an exception in the interim final regulations that permitted plans to impose nonquantitative treatment limitations to the extent that "recognized clinically appropriate standards of care" may permit a difference. The final rules are effective for plan and policy years beginning on or after July 1, 2014.

9. Insurance Exchanges

Although not a legal issue, the technical difficulties associated with the unveiling of the federal online health insurance marketplace constituted one of the most visible health care issues of the year. While recent reports indicate improved performance and rising enrollment, it remains to be seen whether the implementation issues will lead to more significant problems, such as delays in uninsured individuals obtaining health insurance or a reduction in the number of people choosing to purchase health insurance rather than paying the individual mandate tax penalties. The technical issues associated with the launch of the healthcare.gov website also raise the possibility of delays in the implementation of other key components of the Affordable Care Act, such as the (already once delayed) March 31, 2014 deadline for the individual mandate tax penalties. What on the one hand is a limited logistical hiccup in the implementation of a massively complex law, has, on the other hand, generated significant concern and uncertainty regarding health care reform.

10. Medicaid Expansion Developments

The Affordable Care Act was designed to require all states to offer Medicaid eligibility to nondisabled, low-income adults up to 138% of the federal poverty level. This new category is commonly referred to as the expansion population. However, in June 2012, the U.S Supreme Court ruled that the federal government cannot penalize states that do not implement the law's Medicaid expansion provisions with the loss of existing federal Medicaid funding, thereby effectively giving states the option of whether to cover this new category of individuals. Whether or not to cover the expansion population continued to be a contentious policy discussion in many states in 2013. To date, 25 states plus the District of Columbia have opted to provide coverage, while 23 states have not. Two states, Indiana and Pennsylvania, have waiver applications pending with CMS for alternative Medicaid expansion plans. Regardless of whether states choose to offer coverage to the expansion population, the Affordable Care Act will increase the number of individuals, particularly children, who are eligible for Medicaid coverage as a result of several provisions, such as effectively increasing the poverty level thresholds for eligibility, requiring states to cover foster care children until the age of 26, streamlining Medicaid enrollment applications, creating online Medicaid enrollment through the health insurance exchanges, and allowing for hospitals to make presumptive Medicaid eligibility determinations.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Topics
 
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions